ArticleBritish journal of cancer2026
Hypoxia-induced HMGB1/NLRP3/Caspase-1 signaling axis enhances proliferation of oral squamous cell carcinoma.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe hypoxic microenvironment, a common feature of solid tumors, is critically involved in driving cancer malignancy. This research focuses on elucidating the function of high mobility group box 1 (HMGB1), induced by such hypoxia, in the context of oral squamous cell carcinoma (OSCC).
methodsWe first profiled HMGB1 expression patterns in clinical OSCC specimens and evaluated their potential associations with clinicopathological parameters. To functionally characterize HMGB1, we conducted in vitro experiments utilizing silencing strategies. The impact of chronic cyclic hypoxia and HMGB1 depletion on key cellular processes-including proliferation, pyroptosis, and cell cycle-was systematically examined in OSCC cells. Signaling activity along the HMGB1/NLRP3/Caspase-1 axis was determined by immunoblotting. Furthermore, in vivo relevance was substantiated through murine xenograft models and a 4-NQO-induced carcinogenesis protocol.
resultsAnalysis of clinical samples revealed that HMGB1 is constitutively upregulated in OSCC tissues. This elevated expression demonstrated a positive relationship with both increased tumor dimensions and lymph node metastasis. Subsequent Kaplan-Meier survival curves indicated that heightened HMGB1 levels are a marker for unfavorable patient outcomes. Furthermore, in cell culture systems, hypoxia treatment significantly elevates HMGB1 expression levels in OSCC cells. Knockdown of HMGB1 expression inhibits hypoxia-induced NLRP3, cleaved-caspase-1, and HIF-1α expression. Hypoxia treatment markedly enhanced OSCC cell proliferation, induced pyroptosis, and alleviated G2/M phase arrest, while HMGB1 knockdown reversed the pro-tumor effects of hypoxia. In vivo experiments demonstrated that HMGB1 knockdown inhibited tumor growth, whereas NLRP3 or caspase-1 deficiency delayed oral cancer progression.
conclusionOur findings suggested that HMGB1 contributes to the progression of OSCC and has prognostic value. Targeting the hypoxia-induced HMGB1/NLRP3/Caspase-1 signaling axis may offer a viable therapeutic strategy.
Identifiers
42860443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.